Research programme: peroxisome proliferator-activated receptor gamma agonist - Omeros

Drug Profile

Research programme: peroxisome proliferator-activated receptor gamma agonist - Omeros

Alternative Names: PPAR-gamma agonist

Latest Information Update: 10 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Omeros Corporation
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Drug abuse

Most Recent Events

  • 10 May 2017 Preclinical development is ongoing in USA
  • 16 Mar 2017 Omeros Corporation has patent protection for peroxisome proliferator-activated receptor gamma agonists for additive disorders in USA and ex-US countries
  • 04 May 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top